Search

Your search keyword '"Gale, Robert Peter"' showing total 2,658 results
Start Over Author "Gale, Robert Peter"

Refine your results

more »

more »

more »

more »

more »
2,658 results on '"Gale, Robert Peter"'

13. Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders

Author

Lazarus, Hillard M, Pitts, Katherine, Wang, Tisha, Lee, Elinor, Buchbinder, Elizabeth, Dougan, Michael, Armstrong, David G, Paine, Robert, Ragsdale, Carolyn E, Boyd, Timothy, Rock, Edwin P, and Gale, Robert Peter

Subjects
Biomedical and Clinical Sciences, Immunology, Autoimmune Disease, Vaccine Related, Immunotherapy, Immunization, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Humans, Granulocyte-Macrophage Colony-Stimulating Factor, Immune Checkpoint Inhibitors, COVID-19, Macrophages, Monocytes, mononuclear phagocyte, sargramostim, immunomodulation, granulocyte-macrophage colony-stimulating factor, autoimmune pulmonary alveolar proteinosis, wound healing, immune checkpoint inhibitors, Medical Microbiology, Biochemistry and cell biology, Genetics
Abstract

IntroductionEndogenous granulocyte-macrophage colony-stimulating factor (GM-CSF), identified by its ability to support differentiation of hematopoietic cells into several types of myeloid cells, is now known to support maturation and maintain the metabolic capacity of mononuclear phagocytes including monocytes, macrophages, and dendritic cells. These cells sense and attack potential pathogens, present antigens to adaptive immune cells, and recruit other immune cells. Recombinant human (rhu) GM-CSF (e.g., sargramostim [glycosylated, yeast-derived rhu GM-CSF]) has immune modulating properties and can restore the normal function of mononuclear phagocytes rendered dysfunctional by deficient or insufficient endogenous GM-CSF.MethodsWe reviewed the emerging biologic and cellular effects of GM-CSF. Experts in clinical disease areas caused by deficient or insufficient endogenous GM-CSF examined the role of GM-CSF in mononuclear phagocyte disorders including autoimmune pulmonary alveolar proteinosis (aPAP), diverse infections (including COVID-19), wound healing, and anti-cancer immune checkpoint inhibitor therapy.ResultsWe discuss emerging data for GM-CSF biology including the positive effects on mitochondrial function and cell metabolism, augmentation of phagocytosis and efferocytosis, and immune cell modulation. We further address how giving exogenous rhu GM-CSF may control or treat mononuclear phagocyte dysfunction disorders caused or exacerbated by GM-CSF deficiency or insufficiency. We discuss how rhu GM-CSF may augment the anti-cancer effects of immune checkpoint inhibitor immunotherapy as well as ameliorate immune-related adverse events.DiscussionWe identify research gaps, opportunities, and the concept that rhu GM-CSF, by supporting and restoring the metabolic capacity and function of mononuclear phagocytes, can have significant therapeutic effects. rhu GM-CSF (e.g., sargramostim) might ameliorate multiple diseases of GM-CSF deficiency or insufficiency and address a high unmet medical need.

Published
2023

21. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia

Author

Yan, Nan, Wang, Zi-Long, Wang, Xiao-Juan, Gale, Robert Peter, Zhou, Ya-Lan, Zhao, Ming-Yue, Wu, Li-Xin, Liao, Ming-Yue, Yang, Jie, Wang, Chun-Yang, Zhu, Jian-Hua, Jiang, Hao, Jiang, Qian, Liu, Yan-Rong, Chang, Ying-Jun, Xu, Lan-Ping, Zhang, Xiao-Hui, Ma, Tong-Hui, Huang, Xiao-Jun, and Ruan, Guo-Rui

Published
2024
Full Text
View/download PDF

28. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

31. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.

Published
2023
Full Text
View/download PDF

32. Validation of the imatinib-therapy failure model

Author

Zhang, Xiaoshuai, Gale, Robert Peter, Liu, Bingcheng, Huang, Jian, Zhang, Yanli, Du, Xin, Weng, Jianyu, Li, Weiming, Xu, Na, Liu, Xiaoli, Chen, Chunyan, Lin, Hai, Li, Guohui, Liang, Rong, Liu, Zhuogang, Wang, Xiaodong, Zhang, Yanqing, Han, Yanqiu, Liu, Chunshui, Hu, Jianda, Lin, Lie, Yang, Wei, Liu, Zhenfang, Meng, Li, Tu, Chuanqing, Zheng, Caifeng, Zhou, Zeping, Bai, Yanliang, Qiu, Huiying, Chen, Suning, Li, Fei, Guo, Jianxin, Liu, Zelin, Sun, Hui, Zhou, Li, Feng, Ru, Sun, Xiuli, Huang, Xiaojun, and Jiang, Qian

Published
2023
Full Text
View/download PDF

37. A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Author

Zhang, Xiaoshuai, Liu, Bingcheng, Huang, Jian, Zhang, Yanli, Xu, Na, Gale, Robert Peter, Li, Weiming, Liu, Xiaoli, Zhu, Huanling, Pan, Ling, Yang, Yunfan, Lin, Hai, Du, Xin, Liang, Rong, Chen, Chunyan, Wang, Xiaodong, Li, Guohui, Liu, Zhuogang, Zhang, Yanqing, Liu, Zhenfang, Hu, Jianda, Liu, Chunshui, Li, Fei, Yang, Wei, Meng, Li, Han, Yanqiu, Lin, Li’e, Zhao, Zhenyu, Tu, Chuanqing, Zheng, Caifeng, Bai, Yanliang, Zhou, Zeping, Chen, Suning, Qiu, Huiying, Yang, Lijie, Sun, Xiuli, Sun, Hui, Zhou, Li, Liu, Zelin, Wang, Danyu, Guo, Jianxin, Pang, Liping, Zeng, Qingshu, Suo, Xiaohui, Zhang, Weihua, Zheng, Yuanjun, Huang, Xiaojun, and Jiang, Qian

Published
2024
Full Text
View/download PDF

38. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Author

Jimenez Jimenez, Antonio M, De Lima, Marcos, Komanduri, Krishna V, Wang, Trent P, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R, Hildebrandt, Gerhard C, Hogan, William J, Kanakry, Christopher G, Kansagra, Ankit, Kharfan-Dabaja, Mohamed A, Khera, Nandita, Krem, Maxwell M, Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S, Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F, Wirk, Baldeep, Yared, Jean A, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S, Saber, Wael, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Genetics, Transplantation, Pediatric Research Initiative, Childhood Leukemia, Stem Cell Research, Cancer, Clinical Research, Pediatric Cancer, Rare Diseases, Pediatric, Stem Cell Research - Nonembryonic - Human, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Retrospective Studies, Risk Assessment, Transplantation Conditioning, Transplantation, Homologous, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p

Published
2021

42. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author

Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael

Published
2023
Full Text
View/download PDF

43. Thalassaemia in China

Author

Wang, Wei-da, Hu, Fang, Zhou, Dun-hua, Gale, Robert Peter, Lai, Yong-rong, Yao, Hong-xia, Li, Chunfu, Wu, Bing-yi, Chen, Zhu, Fang, Jian-pei, Chen, Sai-juan, and Liang, Yang

Published
2023
Full Text
View/download PDF

45. A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma

Author

Wang, Hua, Fu, Bi-bo, Wuxiao, Zhi-jun, Li, Ya-jun, Huang, Li, Ma, Jie, Zhai, Zhi-min, Guo, Jing, Wu, Yuan-bin, Xu, Zhen-shu, Feng, Jia, Zhou, Sheng-sheng, Chen, Ting-ting, Chen, Xing-gui, Li, Guo-wei, Liu, Ting-zhi, Huang, Hai-bin, Zheng, Run-hui, Li, Yong-hua, Tao, Hong-fang, Zi, Fu-ming, Wu, Fan, Wang, Juan, Zeng, Hui, Fu, Cai-bo, Gale, Robert Peter, Xia, Zhong-jun, and Liang, Yang

Published
2022
Full Text
View/download PDF

49. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

Author

Bejanyan, Nelli, Kim, Soyoung, Hebert, Kyle M, Kekre, Natasha, Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Badawy, Sherif M, Beitinjaneh, Amer, Boelens, Jaap Jan, Diaz, Miguel Angel, Dvorak, Christopher C, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Ganguly, Siddhartha, Gennery, Andrew R, George, Biju, Gergis, Usama, Gómez-Almaguer, David, Vicent, Marta Gonzalez, Hashem, Hasan, Kamble, Rammurti T, Kasow, Kimberly A, Lazarus, Hillard M, Mathews, Vikram, Orchard, Paul J, Pulsipher, Michael, Ringden, Olle, Schultz, Kirk, Teira, Pierre, Woolfrey, Ann E, Saldaña, Blachy Dávila, Savani, Bipin, Winiarski, Jacek, Yared, Jean, Weisdorf, Daniel J, Antin, Joseph H, and Eapen, Mary

Subjects
Transplantation, Regenerative Medicine, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Prevention, Hematology, Rare Diseases, Good Health and Well Being, Adolescent, Adult, Anemia, Aplastic, Bone Marrow Transplantation, Clinical Decision-Making, Disease Management, Graft vs Host Disease, HLA Antigens, Histocompatibility Testing, Humans, Prognosis, Severity of Illness Index, Siblings, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult
Abstract

Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe aplastic anemia (SAA). However, several conditioning regimens can be used for BMT. We evaluated transplant conditioning regimens for BMT in SAA after HLA-matched sibling and unrelated donor BMT. For recipients of HLA-matched sibling donor transplantation (n = 955), fludarabine (Flu)/cyclophosphamide (Cy)/antithymocyte globulin (ATG) or Cy/ATG led to the best survival. The 5-year probabilities of survival with Flu/Cy/ATG, Cy/ATG, Cy ± Flu, and busulfan/Cy were 91%, 91%, 80%, and 84%, respectively (P = .001). For recipients of 8/8 and 7/8 HLA allele-matched unrelated donor transplantation (n = 409), there were no differences in survival between regimens. The 5-year probabilities of survival with Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG, and Cy/ATG were 77%, 80%, 75%, and 72%, respectively (P = .61). Rabbit-derived ATG compared with equine-derived ATG was associated with a lower risk of grade II to IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 0.39; P < .001) but not chronic GVHD. Independent of conditioning regimen, survival was lower in patients aged >30 years after HLA-matched sibling (HR, 2.74; P < .001) or unrelated donor (HR, 1.98; P = .001) transplantation. These data support Flu/Cy/ATG and Cy/ATG as optimal regimens for HLA-matched sibling BMT. Although survival after an unrelated donor BMT did not differ between regimens, use of rabbit-derived ATG may be preferred because of lower risks of acute GVHD.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results